by Lupus Foundation, Ohio | Oct 2, 2026 | Lupus Foundation of America, News & Events
A Phase I study of the investigational CAR-T cell therapy prulacabtagene leucel (prula-cel) found that some people with SLE, including those with lupus nephritis (LN), achieved remission and kidney-related responses after a single treatment. This post was originally...
by | Oct 1, 2026 | Lupus Foundation of America
Purple for a Purpose partner and Inspira founder Rachel shares about her mom’s journey with lupus and how it inspired her company. This post was originally published on this...
by Lupus Foundation, Ohio | Sep 30, 2026 | Lupus Foundation of America, News & Events
A new study found that dietary supplement use is widespread among adults living with systemic lupus erythematosus (SLE), with more than 80% of participants reporting use of at least one supplement and more than half using two or more. This post was originally...
by Adrienne Fernandez | Sep 29, 2026 | Lupus Foundation of America
The Lupus Foundation of America Responds to CMS Medicaid Work Requirements Rule The Lupus Foundation of America responded to the Centers for Medicare & Medicaid Services (CMS) recently issued regulations that will govern the implementation of Medicaid cuts enacted...
by Lupus Foundation, Ohio | Sep 29, 2026 | Lupus Foundation of America, News & Events
A new study found that people with systemic lupus erythematosus (SLE) who also had depression, anxiety and/or post-traumatic stress disorder (PTSD) experienced higher rates of emergency department visits and hospitalizations than those without these diagnoses. This...
by Lupus Foundation, Ohio | Sep 25, 2026 | Lupus Foundation of America, News & Events
Immunovant has announced topline results from a proof-of-concept study evaluating treatment imeroprubart (IMVT-1402) in people with cutaneous lupus erythematosus (CLE). This post was originally published on this...
